United Arab Emirates Pharmaceuticals & Healthcare Report

Published 24 June 2015

  • 131 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
United Arab Emirates Pharmaceuticals & Healthcare Report

BMI View: We uphold our outlook for continued strong growth in the UAE's pharmaceutical and healthcare markets, driven by expanding insurance coverage and medical tourism. Our growth outlook is supported by positive financial results for pharmaceutical distributor Al Ittihad Drug Store, and healthcare providers Al Noor Hospitals and NMC Health, with these results a good indicator of market growth. These key factors, boosted by strong economic performance and a relatively stable political environment make the UAE one of the most attractive markets for multinational drugmakers looking to set up operations in the Middle East.

Headline Expenditure Projections

  • Pharmaceuticals: AED9.46bn (USD2.58bn) in 2014 to AED10.29bn (USD2.80bn) in 2015; +8.7% in local currency terms and +8.8% US dollar terms. Forecast revised upwards form last quarter.

  • Healthcare: AED50.79bn (USD13.83bn) in 2014 to AED54.29bn (USD14.79bn) in 2015; +6.9% in local currency terms and +7.0% US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index

The UAE is one of the most rewarding markets for pharmaceutical and healthcare providers in the Middle East and African region. It has a fast-growing private healthcare sector, which brings with it demand for innovative and patented drugs. The UAE's relative political stability also contributes to the country's high regional score. In our Q3 2015 Indices, the UAE scores 59.4 and is the most attractive market in our Middle East and African regional matrix followed closely by Saudi Arabia (59.3).

Key Trends & Developments

June

  • The UAE government has launched a new health-insurance programme in Dubai with the aim of supporting nationals not covered under any other government-funded health-insurance scheme, reports the National. The scheme, dubbed 'Sa'ada', is expected to benefit 130,000 people by offering them healthcare at 23 private hospitals and more than 500 medical clinics in and around Dubai. Interested candidates can...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (United Arab Emirates 2011-2019)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United Arab Emirates 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United Arab Emirates 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United Arab Emirates 2011-2019)
20
Prescription Drug Market Forecast
21
Table: UAE Healthcare Demand Split By Therapeutic Area
22
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United Arab Emirates 2011-2019)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United Arab Emirates 2011-2019)
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United Arab Emirates 2011-2019)
29
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United Arab Emirates 2011-2019)
31
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (United Arab Emirates 2013-2019)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (United Arab Emirates 2013-2019)
33
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Fiscal Position Remains Solid
37
Oil Sector To See Only Marginal Gains
38
Risks To Outlook
39
Table: Economic Activity (United Arab Emirates 2009-2018)
40
Table: GDP By Expenditure (United Arab Emirates 2011-2018)
40
Industry Risk Reward Ratings
42
Middle East And Africa Risk/Reward Index
42
United Arab Emirates Risk/Reward Index
50
Rewards
50
Risks
50
Market Overview
52
Industry Trends And Developments
53
Epidemiology
53
Table: UAE Healthcare Demand Split By Therapeutic Area
54
Healthcare Sector
59
Healthcare Sector Developments
60
Health Insurance
65
Research & Development
69
Regulatory Development
72
Regulatory Regime
72
Regulatory Developments
73
Pharmacovigilance
74
Pharmaceutical Advertising
75
Intellectual Property Issues
75
Pricing Regime
78
Pricing And Reimbursement Developments
79
Regional Harmonisation
81
Competitive Landscape
85
Pharmaceutical Sector
85
Table: Abu Dhabi's Top Five Best Selling Drugs In Value Terms By Therapeutic Area
85
Domestic Industry
86
Foreign Industry
88
Recent Company Developments
88
Pharmaceutical Distribution And Retail
89
Recent Developments
90
Company Profile
91
Gulf Pharmaceutical Industries (Julphar)
91
Modern Pharmaceutical Company
95
Neopharma
97
Medpharma
100
GlaxoSmithKline
102
Pfizer
104
Novartis
106
Johnson & Johnson
109
Sanofi-Aventis
111
Abbott Laboratories
113
Merck & Co
115
Demographic Forecast
117
Demographic Outlook
117
Table: Population Headline Indicators (United Arab Emirates 1990-2025)
118
Table: Key Population Ratios (United Arab Emirates 1990-2025)
118
Table: Urban/Rural Population & Life Expectancy (United Arab Emirates 1990-2025)
119
Table: Population By Age Group (United Arab Emirates 1990-2025)
119
Table: Population By Age Group % (United Arab Emirates 1990-2025)
120
Glossary
122
Methodology
124
Pharmaceutical Expenditure Forecast Model
124
Healthcare Expenditure Forecast Model
124
Notes On Methodology
125
Risk/Reward Index Methodology
126
Index Overview
127
Table: Pharmaceutical Risk/Reward Index Indicators
127
Indicator Weightings
128

The United Arab Emirates Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the United Arab Emirates pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for United Arab Emirates, to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Emirati pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United Arab Emirates.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc